BioCorteX

BioCorteX is a life sciences technology company focused on capturing the complex relationship between humans and bacteria to answer a fundamental question in drug development: will this drug work for a given individual? The company exists to address a critical gap in modern therapeutics — the fact that age, ethnicity, diet, and gender all influence the composition of an individual's microbiome, which in turn determines whether a drug treatment will have a positive or negative outcome. Despite this variability, current drug development approaches remain largely uniform, leading to failed clinical trials, poor patient outcomes, limited options for diverse populations, and significant financial costs across the healthcare and pharmaceutical industries.

BioCorteX serves pharmaceutical and biotech organizations engaged in drug discovery and development, offering a platform that generates actionable insights by modeling the mechanistic links between the microbiome and differential treatment responses. The company's goal is to enable the creation of sophisticated, tailored therapeutics that account for differences across individuals and human populations — moving away from one-size-fits-all treatments toward options that work successfully for diverse communities of patients suffering from life-changing diseases. BioCorteX has registered offices in London, New York, and Adelaide, and operates in strategic partnership with organizations including CD Biopharma to accelerate global precision oncology.

Core Platform Products

• Carbon Knowledge™ — The world's most extensive and varied knowledge graph of microbiome samples. It consists of millions of organic microbiome samples — including human, animal, soil, and water microbiomes — carefully selected from over 165 geopolitical regions and representing diverse populations worldwide. Carbon Knowledge serves as the foundational data layer underpinning BioCorteX's analytical capabilities.
• Carbon Mirror™ — A one-of-a-kind foundational biology emulator built upon Carbon Knowledge. Carbon Mirror uncovers hidden interactions between bacteria, the human immune system, diseases, and pharmaceutical interventions. It enables BioCorteX to test mechanistic links between the varied microbiome and different treatment responses, generating unparalleled insights that add value throughout the drug discovery and development process.

Scientific Approach to Therapeutics

• BioCorteX takes a multi-layered approach to understanding how drugs interact with bacteria, examining three distinct levels of interaction.
• Direct drug-bacteria metabolism: The direct effect that drugs have on bacterial metabolism and vice versa.
• Indirect effects on host physiology: How bacteria indirectly influence the broader human physiological response to a drug treatment.
• Local tissue-level effects: The localized impact of bacteria in specific tissues, such as the tumour microbiome, which is particularly relevant in oncology applications.
• This three-layer framework allows BioCorteX to model complex, individualized drug responses that conventional approaches cannot capture.

Key Applications and Industry Focus

• BioCorteX's platform is applicable across the full drug discovery and development lifecycle, providing insights that support target identification, candidate selection, and clinical trial design.
• The company has a notable focus on oncology, including work on antibody-drug conjugate (ADC) cancer treatments, where it has uncovered critical bacteria interactions enabled by Google Cloud infrastructure.
• BioCorteX addresses the challenges of moving oncology assets between geopolitical regions, a key concern given the microbiome's sensitivity to regional and demographic variation.
• The platform's insights support the development of precision medicine strategies, enabling pharmaceutical partners to design treatments that are more likely to succeed across diverse patient populations.

Team and Investors

• BioCorteX was co-founded by Nik Sharma (CEO) and Mo Alomari (CTO), and is supported by a multidisciplinary team including senior clinician scientists, data scientists, microbiome data scientists, data engineers, platform engineers, software engineers, and graph engineers.
• The company's board includes partners from Sofinnova Partners (Edward Kliphuis) and Hoxton Ventures (Hussein Kanji), reflecting backing from established life sciences and technology-focused investment firms.

By combining the world's largest biology-based microbiome knowledge graph with a powerful foundational emulator, BioCorteX is uniquely positioned to help pharmaceutical and biotech companies develop more effective, personalized therapeutics — positively changing the future of drug development worldwide.